Get started
Work

Addendum: Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial

Year: 2025
Type: article
Abstract: In the original version of this manuscript, we reported a post-hoc analysis of long-term clinical outcomes of a randomized multicenter clinical trial comparing two experimental melanoma vaccines, with or without low dose cyclophosphamide (Cy). The data supported prolonged long-term survival of patients treated with a vaccine comprised of 12 class I MHC-restricted peptides designed to induce CD8 + T cell responses (12MP) plus 6 class II MHC-restricted peptides designed to induce CD4 + T cell responses to melanoma antigens (6MHP), compared to vaccination with 12MP plus a tetanus toxoid peptide for activation of CD4 + T cells that were not melanoma-cognate.
DOI: 10.1038/s41467-025-63690-x
Authors: Emily K. Ninmer, Hong Zhu, Kimberly A. Chianese-Bullock, Margaret von Mehren, Naomi B. Haas, Merrick I. Ross, Lynn T. Dengel, Craig L. Slingluff
Institutions: University of Virginia Cancer Center, University of Virginia, Fox Chase Cancer Center, University of Pennsylvania, The University of Texas MD Anderson Cancer Center, University of Virginia Health System
Language: English
Subfield: Immunology
Open Access status: gold
Estimated APC paid: $6,990
OpenAlex ID: W4414016605
FWCI:
Cites:
Cited by:
Related to: 10